Taysha Gene Therapies Inc (TSHA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Taysha Gene Therapies Inc stock (TSHA) is currently trading at $4.58. Taysha Gene Therapies Inc PS ratio (Price-to-Sales) is 121.40. Analyst consensus price target for TSHA is $11.29. WallStSmart rates TSHA as Sell.
- TSHA PE ratio analysis and historical PE chart
- TSHA PS ratio (Price-to-Sales) history and trend
- TSHA intrinsic value — DCF, Graham Number, EPV models
- TSHA stock price prediction 2025 2026 2027 2028 2029 2030
- TSHA fair value vs current price
- TSHA insider transactions and insider buying
- Is TSHA undervalued or overvalued?
- Taysha Gene Therapies Inc financial analysis — revenue, earnings, cash flow
- TSHA Piotroski F-Score and Altman Z-Score
- TSHA analyst price target and Smart Rating
Taysha Gene Therapies Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Taysha Gene Therapies Inc (TSHA) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Taysha Gene Therapies Inc (TSHA) Key Strengths (2)
Revenue surging 171.30% year-over-year
95.41% of shares held by major funds and institutions
Supporting Valuation Data
Taysha Gene Therapies Inc (TSHA) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 121.4x annual revenue
Very expensive at 5.5x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Taysha Gene Therapies Inc (TSHA) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 171.30%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (121.40), Price/Book (5.50) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -68.40%, Operating Margin at -516.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -68.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 171.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TSHA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TSHA's Price-to-Sales ratio of 121.40x sits near its historical average of 114.37x (60th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 65% below its historical high of 345.96x set in Sep 2023, and 363% above its historical low of 26.24x in Jan 2024. Over the past 12 months, the PS ratio has expanded from ~63.4x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Taysha Gene Therapies Inc (TSHA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Taysha Gene Therapies Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 10M with 171% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 171% YoY, reaching 10M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 252% of revenue (25M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -27M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Taysha Gene Therapies Inc maintain 171%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Taysha Gene Therapies Inc.
Bottom Line
Taysha Gene Therapies Inc is a high-conviction growth story with revenue accelerating at 171% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(18 last 3 months)
| Insider | Type | Shares |
|---|---|---|
ALAM, KAMRAN CHIEF FINANCIAL OFFICER | Sell | -1,655 |
Data sourced from SEC Form 4 filings
Last updated: 8:23:14 AM
About Taysha Gene Therapies Inc(TSHA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas.